Merck & Co Inc

NYSE:MRK  
80.96
+0.38 (+0.47%)
4:00:00 PM EDT: $80.88 -0.08 (-0.10%)
Products, Regulatory, Other Pre-Announcement

Merck Announces Supply Agreement With U.S. Government For Molnupiravir, An Investigational Oral Antiviral Candidate For Treatment Of Mild To Moderate Covid-19

Published: 06/09/2021 12:15 GMT
Merck & Co Inc (MRK) - Merck Announces Supply Agreement With U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate Covid-19.
Merck & Co Inc - U.S. Government Commits to Purchase About 1.7 Million Courses of Molnupiravir Upon Issuance of Eua Or Approval by FDA.
Merck & Co Inc - If Molnupiravir Receives Eua Or Approval by FDA, Co Will Receive About $1.2 Billion to Supply About 1.7 Million Courses to U.S. Government.
Merck & Co Inc - Expects to Have More Than 10 Million Courses of Molnupiravir Available by End of 2021.
Merck & Co - Entered Agreements for Molnupiravir With Manufacturers to Accelerate Availability of Molnupiravir in 104 Low- and Middle-income Countries.
Merck & Co Inc - Currently in Discussions With Other Countries Interested in Advance Purchase Agreements for Molnupiravir.